Published in Blood Weekly, July 15th, 2004
The blinded review of data by an independent panel of experts was agreed upon with the U.S. Food and Drug Administration (FDA) as a next step in the U.S. regulatory submission for the Intercept Blood System for platelets.
The analysis of primary patient records performed under the direction of an independent contract research organization...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.